Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Skin autofluorescence: Correlation with measures of diabetic sensorimotor neuropathy.

Stirban AO, Bondor CI, Florea B, Veresiu IA, Gavan NA.

J Diabetes Complications. 2018 Sep;32(9):851-856. doi: 10.1016/j.jdiacomp.2018.06.014. Epub 2018 Jul 5.

PMID:
30025785
2.

Advances in the management of diabetic neuropathy.

Várkonyi T, Körei A, Putz Z, Martos T, Keresztes K, Lengyel C, Nyiraty S, Stirban A, Jermendy G, Kempler P.

Minerva Med. 2017 Oct;108(5):419-437. doi: 10.23736/S0026-4806.17.05257-0. Epub 2017 May 25. Review.

PMID:
28541026
3.

A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.

Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N.

Cardiovasc Diabetol. 2017 Jan 21;16(1):13. doi: 10.1186/s12933-016-0493-3.

4.

Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.

Stirban AO, Andjelkovic M, Heise T, Nosek L, Fischer A, Gastaldelli A, Herz M.

Diabetes Obes Metab. 2016 Jul;18(7):711-5. doi: 10.1111/dom.12620. Epub 2016 Feb 1.

PMID:
26663152
5.

Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.

Marquard J, Stirban A, Schliess F, Sievers F, Welters A, Otter S, Fischer A, Wnendt S, Meissner T, Heise T, Lammert E.

Diabetes Obes Metab. 2016 Jan;18(1):100-3. doi: 10.1111/dom.12576. Epub 2015 Oct 26.

6.

Vascular Effects of Dietary Advanced Glycation End Products.

Stirban A, Tschöpe D.

Int J Endocrinol. 2015;2015:836498. doi: 10.1155/2015/836498. Epub 2015 May 18. Review.

7.

Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment.

Marquard J, Otter S, Welters A, Stirban A, Fischer A, Eglinger J, Herebian D, Kletke O, Klemen MS, Stožer A, Wnendt S, Piemonti L, Köhler M, Ferrer J, Thorens B, Schliess F, Rupnik MS, Heise T, Berggren PO, Klöcker N, Meissner T, Mayatepek E, Eberhard D, Kragl M, Lammert E.

Nat Med. 2015 Apr;21(4):363-72. doi: 10.1038/nm.3822. Epub 2015 Mar 16.

PMID:
25774850
8.

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics.

Polidori D, Sha S, Heise T, Natarajan J, Artis E, Wang SS, Vaccaro N, Rothenberg P, Stirban A.

Clin Pharmacol Drug Dev. 2015 Jan;4(1):12-7. doi: 10.1002/cpdd.115. Epub 2014 May 28.

PMID:
27127999
9.

Microvascular dysfunction in the context of diabetic neuropathy.

Stirban A.

Curr Diab Rep. 2014;14(11):541. doi: 10.1007/s11892-014-0541-x. Review.

PMID:
25189434
10.

Skin Autofluorescence - A Non-invasive Measurement for Assessing Cardiovascular Risk and Risk of Diabetes.

Stirban A, Heinemann L.

Eur Endocrinol. 2014 Aug;10(2):106-110. doi: 10.17925/EE.2014.10.02.106. Epub 2014 Aug 28. Review.

11.

Measurement of Lens Autofluorescence for Diabetes Screening.

Stirban A.

J Diabetes Sci Technol. 2014 Jan;8(1):50-53. Epub 2014 Jan 1.

12.

Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.

Stirban A, Gawlowski T, Roden M.

Mol Metab. 2013 Dec 7;3(2):94-108. doi: 10.1016/j.molmet.2013.11.006. eCollection 2014 Apr. Review.

13.

Effects of n-3 polyunsaturated fatty acids (PUFAs) on circulating adiponectin and leptin in subjects with type 2 diabetes mellitus.

Stirban A, Nandrean S, Götting C, Stratmann B, Tschoepe D.

Horm Metab Res. 2014 Jun;46(7):490-2. doi: 10.1055/s-0033-1363225. Epub 2013 Dec 19.

PMID:
24356795
14.

Comment on "Advanced glycation endproducts in food and their effects on health" by Poulsen et al. (2013) Food and Chemical Toxicology 60, 10-37.

Stirban A, Tschoepe D.

Food Chem Toxicol. 2014 Feb;64:411. doi: 10.1016/j.fct.2013.12.001. Epub 2013 Dec 4. No abstract available.

PMID:
24316312
15.

Variability of skin autofluorescence measurement over 6 and 12 weeks and the influence of benfotiamine treatment.

Stirban A, Pop A, Fischer A, Heckermann S, Tschoepe D.

Diabetes Technol Ther. 2013 Sep;15(9):733-7. doi: 10.1089/dia.2013.0103. Epub 2013 Aug 21.

PMID:
23964994
16.

Noninvasive skin fluorescence spectroscopy for diabetes screening.

Stirban A.

J Diabetes Sci Technol. 2013 Jul 1;7(4):1001-4.

17.
18.

Current options and perspectives in the treatment of diabetic neuropathy.

Várkonyi T, Putz Z, Keresztes K, Martos T, Lengyel C, Stirban A, Jermendy G, Kempler P.

Curr Pharm Des. 2013;19(27):4981-5007. Review.

PMID:
23278494
19.

Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins.

Stirban A, Kotsi P, Franke K, Strijowski U, Cai W, Götting C, Tschoepe D.

Diabetes Care. 2013 May;36(5):1278-82. doi: 10.2337/dc12-1489. Epub 2012 Dec 13.

20.

Benfotiamine counteracts smoking-induced vascular dysfunction in healthy smokers.

Stirban A, Nandrean S, Kirana S, Götting C, Veresiu IA, Tschoepe D.

Int J Vasc Med. 2012;2012:968761. doi: 10.1155/2012/968761. Epub 2012 Oct 3.

Supplemental Content

Loading ...
Support Center